Inhibition of Plk1 activity by the Plk1 inhibitors volasertib effectively reduced the phosphorylation of AKT, mTOR and S6 in leukemia and Burkitt lymphoma cells (Choi et al., 2023; Chen and Pei, 2020). Here, MTOR is linked to Burkitt lymphoma.